PubMed:19880293 / 2005-2225 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T19","span":{"begin":0,"end":220},"obj":"Sentence"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-entities","denotations":[{"id":"6699","span":{"begin":35,"end":40},"obj":"GeneOrGeneProduct"},{"id":"6700","span":{"begin":40,"end":51},"obj":"SequenceVariant"},{"id":"6701","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"},{"id":"6702","span":{"begin":158,"end":166},"obj":"OrganismTaxon"}],"attributes":[{"id":"A40","pred":"db_id","subj":"6699","obj":"NCBIGene:50943"},{"id":"A41","pred":"db_id","subj":"6700","obj":"c|Allele|AC|-3279"},{"id":"A42","pred":"db_id","subj":"6701","obj":"MESH:D011565"},{"id":"A43","pred":"db_id","subj":"6702","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T10","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0005083"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T36","span":{"begin":35,"end":40},"obj":"GeneOrGeneProduct"},{"id":"T37","span":{"begin":46,"end":51},"obj":"GeneOrGeneProduct"},{"id":"T38","span":{"begin":94,"end":99},"obj":"GeneOrGeneProduct"},{"id":"T39","span":{"begin":148,"end":157},"obj":"GeneOrGeneProduct"},{"id":"T40","span":{"begin":168,"end":172},"obj":"GeneOrGeneProduct"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T24","span":{"begin":35,"end":40},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":46,"end":51},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":148,"end":157},"obj":"GeneOrGeneProduct"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T10","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A10","pred":"originalLabel","subj":"T10","obj":"D011565"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T14","span":{"begin":35,"end":40},"obj":"GeneOrGeneProduct"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T12","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0005083"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T14","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A14","pred":"ID:","subj":"T14","obj":"D011565"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T14","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A14","pred":"#label","subj":"T14","obj":"D011565"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T5","span":{"begin":158,"end":166},"obj":"OrganismTaxon"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T14","span":{"begin":35,"end":40},"obj":"GeneOrGeneProduct"},{"id":"T47728","span":{"begin":148,"end":157},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T94228","span":{"begin":158,"end":166},"obj":"OrganismTaxon"}],"attributes":[{"id":"A14","pred":"#label","subj":"T47728","obj":"D011565"}],"text":"In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score \u003e20; adjusted OR=1.97, 95% CI=1.41-2.75)."}